Oncology Pipelines (NJ area) |
|
| Roche (in-house, excluding partners) |
| Target | Mechanism of Action | Stage | Status |
R1530 | Multiple TKs | Multikinase inhibitor. Disrupts cell cycle, has anti-angiogenic properties. Inhibits VEGFR1/2/3, PDGFRß, Flt-3, FGFR1/2, etc. | Phase I | Ongoing |
R4733 | G-secretase | gamma-secretase inhibitor | Phase I - Solid tumors | Ongoing
|
R547 | CDK1/2/4 | Cell cycle block at G1 and G2 phases and induction of apoptosis | Phase I - Solid tumors | Ongoing
|
R7112 | p53-MDM2 | Antagonist of p53-MDM2 interactions | Phase I - Solid tumors | Ongoing |
| | | | |
Schering-Plough (in-house, excluding partners) |
Pegintron | | pegylated interferon alfa-2b | Phase I-III - Melanoma | |
Temodar | DNA | cytotoxic alkylating agent / chemotherapy | Phase III - Melanoma | Ongoing |
SCH66336 (Sarasar) | FT | Inhibits multiple farnesyl-transferases in the cell leading to the inhibition of ras and rheb activity. | Phase I - Brain Cancer Phase II - Breast Cancer | Ongoing |
SCH727965 | CDK1/2/9 | Cell Cycle | Phase II - Breast Cancer, Lung | Ongoing |
SCH717454 | IGF1-R | Antibody binds to the human IGF-1R, neutralizes IGF-1 binding and inhibits IGF-1R auto-phosphorylation. | Phase II - Colon, Sarcoma | Ongoing |
| | | | |
BMS (in-house, excluding partners) |
Sprycel | Multiple TKs | BMS-354825, Dasatinib. Inhibits several tyrosine kinases, including BCR/ABL and SRC | Phase II - Breast,Prostate Cancer | Ongoing
|
Angiocept | VEGFR2 | Specific VEGFR2 pathway antagonist | |
|
Brivanib | VEGFR, FGFR | BMS-582664, VEGFR, FGFR driven tumors | Phase III - Metastatic Colorectal Cancer | Ongoing |
Ixempra | Tubulin | Ixabepilone, nontaxane antimicrotubule agent | Phase II - Pancreatic, NSCL | Ongoing |
BMS641988 | Androgen Receptor | Androgen receptor antagonist | Phase I - Prostate Cancer | Ongoing |
BMS690514 | Dual Kinase | dual inhibitor of pan-HER kinase and VEGFR-2 | Phase I | Ongoing |
BMS663513 | CD137 | fully-human MAb agonist against CD137, enhances anti-tumour immune response | Phase I | Ongoing |
BMS743816 | IGF1-R | Insulin like growth factor 1 antagonist | Preclinical | |
| MET | MET kinase inhibitor | Preclinical | |
| SMO | SMO receptor inhibitor ? hedgehog signaling inhibitor | Preclinical | |
| HSP90 | Heat shock protein 90 antagonist | Preclinical | |
| | | | |